Science Pool

Evotec receives € 3 m milestone payment for Bayer starting Phase II clinical development of DNP programme

Evotec SE announced today that the Company received a € 3 m milestone payment from Bayer AG as a result of another promising small molecule from the Evotec-Bayer multi-target research alliance advancing into Phase II clinical development as a potential treatment for diabetic neuropathic pain (“DNP”).

Read More